Certificate under Regulation 74(5) of SEBI(Depositories and Participants)Regulations 2018 for the quarter ended 31st December 2025 ...
The latest update on Ginkgo Bioworks Holdings has reset its fair value anchor from US$12.00 to US$10.00, reflecting a more cautious stance on the stock's long term potential. This comes alongside a ...
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 10, 2026 / New to The Street, the nationally syndicated business ...
1d
The Living Urn’s Tree Nurseries are Well Stocked in Anticipation of Continued Strong Demand in 2026
The company has thousands of trees and flowering shrubs in stock to supply an increase in demand for its unique ...
Hisamitsu Pharmaceutical Co. Inc. President and CEO Kazuhide Nakatomi is leading a management buyout to take the company private, citing mounting drug pricing pressures and tougher listing ...
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
NEW YORK, Jan. 8, 2026 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL). Such investors are advised to contact ...
Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month. However, the scrip has declined ...
The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback